Background For many chronic immune system disorders, the available treatments provide
several options for route of administration. The objective of this systematic literature review is …

Background Pneumonia with severe respiratory failure represents the principal cause of
death in COVID-19, where hyper-inflammation plays an important role in lung damage. An …

Objectives To evaluate retention, efficacy, and safety of subcutaneous (SC) abatacept over 2
years in patients with moderate-to-severe RA in the A batacept S ub C utane O us in R …

Objectives To compare treatment effectiveness in rheumatoid arthritis (RA) patients naïve to
biological disease-modifying antirheumatic drugs (bDMARDs) treated with tocilizumab …

Aim: Several studies have found subcutaneous (SC) and intravenous (IV) administration of
similar drugs for long-lasting immunological and autoimmune diseases to have similar …

Objective This post hoc analysis evaluated the safety and efficacy of open‐label sarilumab
in patients with rheumatoid arthritis (RA) who completed the phase III double‐blind …

Letters to the Editor 978 https://academic. oup. com/rheumatology sc tocilizumab is an
acceptable alternative to iv tocilizumab. No details about the cause of switching were …

Randomised controlled trials (RCTs) are considered the “gold standard” to establish drug
efficacy, but they have typically a short follow-up and include only a limited number of …

COVID-19, a disease caused by the novel coronavirus SARS-CoV-2, has produced a
serious emergency for global public health, placing enormous stress on national health …

Background Tocilizumab prevents the clinical worsening of chronic active antibody-
mediated rejection (CAAMR) in kidney transplant recipients. Following a global shortage of …